Peptide LibraryTestagen
Also known as: Testis bioregulator, Lys-Glu-Asp-Gly
Testagen (also called Testis bioregulator or Lys-Glu-Asp-Gly) is a khavinson endocrine bioregulator. Testagen is Lys-Glu-Asp-Gly, a synthetic tetrapeptide in the Khavinson series associated with testicular tissue. The proposed mechanism is the series hypothesis of short peptides binding DNA promoter regions in the nucleus and modulating transcription, with reported effects on Leydig and Sertoli cell protein synthesis and on reproductive parameters in animal models.
For research use only.
Key Facts
- CAS
- 1026993-38-3
- Molecular Weight (MW)
- 447.44 g/mol
- Half-life
- Not established (limited public PK data; primarily research context)
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- Testicular cells (proposed)
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Oct 2026 and Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 15
- Listed offers
- 19
- Median price per mg
- $3.25/mg
- Typical $2.89–$3.40/mg
Research summary
Short peptide sold as a testicular/endocrine bioregulator. Not FDA-approved; not a testosterone secretagogue with modern RCT evidence.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studies3 reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Testagen profile summarises 4 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Testagen dosage: no established human dose
Testagen has no established human dosage. It is the synthetic tetrapeptide Lys-Glu-Asp-Gly (KEDG), and no human study of it is indexed in PubMed or registered on ClinicalTrials.gov. Its published work is in chickens and cell culture, and in those papers KEDG is described as a pituitary peptide, not a testis peptide.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: Testagen (Lys-Glu-Asp-Gly) is a short synthetic peptide in the Khavinson series. The indexed animal studies are in chickens and describe KEDG as synthesised from the amino-acid make-up of anterior pituitary peptide complexes; they measure thyroid and thymus outcomes, not testis or testosterone outcomes, and their abstracts give no dose. No human has been given KEDG in an indexed study, so nothing here establishes a human dose, route or interval.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Preclinical — KEDG in neonatally hypophysectomised chickens (2008)Preclinical · Animal study | Chickens whose pituitary gland was removed after hatching | Not stated in the indexed abstract (non-human) | Not stated in the indexed abstract | — | 40 days | Higher thyrotropic and thyroid hormone levels and recovery of thyroid structure | Effect of tetrapeptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the structure and function of the thyroid gland in neonatally hypophysectomized chickens. Bull Exp Biol Med. 2008. |
| Preclinical — KEDG and the thymus in hypophysectomised young and old birds (2013)Preclinical · Animal study | Young and old chickens after pituitary removal | Not stated in the indexed abstract (non-human) | Not stated in the indexed abstract | — | — | Recovery of thymus structure, more marked with KEDG than with AEDG | Effect of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the morphology of the thymus in hypophysectomized young and old birds. Bull Exp Biol Med. 2013. |
| In vitro — cell entry and DNA binding of short peptides including testagen (2011)Preclinical · Cell-culture and biochemical study | HeLa cells and isolated DNA fragments | Not stated in the indexed abstract; tested in the laboratory, not given to an organism | In vitro | — | — | Labelled testagen entered the cytoplasm, nucleus and nucleolus, and bound DNA fragments in a sequence-dependent way | Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011. |
Where sources disagree
- Testagen is described by sellers as a testis or testosterone bioregulator, with daily milligram protocols. No indexed study measures a testis or hormone outcome in people, and no primary source for those figures could be identified.
- "Testagen TDS" on ClinicalTrials.gov is a testosterone skin product with a similar name. It is unrelated to the peptide.
- Testagen and Testoluten are different products; the Testoluten profile covers the testis extract capsules.
Reconstitution
Common research vial sizes: 20 mg, 50 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 20 mg | 2 mL | 10 mg/mL | 100 mcg per 0.01 mL |
| 50 mg | 5 mL | 10 mg/mL | 100 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Reconstitution Guide
- If lyophilized: reconstitute with bacteriostatic water per lab SOP (research only)
- Injection Sites
- Abdomen (subQ)
- Concentration Example
- 20 mg vial reconstituted with 2 mL = 10 mg/mL
- Timing Notes
- Often taken in the morning; consistency emphasized in short peptide protocols
- Expected Onset
- Variable; proposed cellular signaling effects over weeks
Sequence & molecular data
| Amino acid sequence | H Lys Glu Asp Gly OH (KEDG) |
|---|---|
| Molecular formula | C17H29N5O9 |
| Molecular weight | 447.44 g/mol |
| CAS number | 1026993-38-3 |
| Half-life | Not established (limited public PK data; primarily research context) |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Testagen is Lys-Glu-Asp-Gly, a synthetic tetrapeptide in the Khavinson series associated with testicular tissue. The proposed mechanism is the series hypothesis of short peptides binding DNA promoter regions in the nucleus and modulating transcription, with reported effects on Leydig and Sertoli cell protein synthesis and on reproductive parameters in animal models. Supporting evidence is cell-culture and cytogenetic work from a single group in Russian-language publications. It is not a treatment for hypogonadism, has no controlled human efficacy data, and is not a substitute for approved testosterone therapy.
Origin
Synthetic short peptide.
Targets
Studies
- Effect of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the morphology of the thymus in hypophysectomized young and old birds
- [Effects of Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly peptides on hormonal activity and thyroid morphology in hypophysectomized mature and old birds]
- Effects of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on hormonal activity and structure of the thyroid gland in hypophysectomized young chickens and old hens
- [Effects of hypophyseal Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly synthetic peptides on immunity, hemostasis, morphology and functions of the thyroid gland in neonatally hypophysectomized chicken and one-year-old birds]
Research statistics
7 PubMed publications · 0.0% human clinical research · 1 registered trial
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Testagen is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
Testagen side effects
Testagen has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Not characterized
Stacking
Common stacking partners
Combinations that include Testagen, with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Testagen: frequently asked questions
What is Testagen?
Short peptide sold as a testicular/endocrine bioregulator. Not FDA-approved; not a testosterone secretagogue with modern RCT evidence.
How does Testagen work?
Testagen is Lys-Glu-Asp-Gly, a synthetic tetrapeptide in the Khavinson series associated with testicular tissue. The proposed mechanism is the series hypothesis of short peptides binding DNA promoter regions in the nucleus and modulating transcription, with reported effects on Leydig and Sertoli cell protein synthesis and on reproductive parameters in animal models.
Is Testagen FDA approved?
No. Testagen is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Testagen?
Reported half-life for Testagen is Not established (limited public PK data; primarily research context). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What is the amino acid sequence of Testagen?
Testagen has the sequence H Lys Glu Asp Gly OH (KEDG). Its molecular formula is C17H29N5O9.
What peptides are similar to Testagen?
Compounds most often compared with Testagen include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Effect of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the morphology of the thymus in hypophysectomized young and old birds — Bull Exp Biol Med, 2013External reference
- [Effects of Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly peptides on hormonal activity and thyroid morphology in hypophysectomized mature and old birds] — Adv Gerontol, 2011External reference
- Effects of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on hormonal activity and structure of the thyroid gland in hypophysectomized young chickens and old hens — Bull Exp Biol Med, 2011External reference
- [Effects of hypophyseal Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly synthetic peptides on immunity, hemostasis, morphology and functions of the thyroid gland in neonatally hypophysectomized chicken and one-year-old birds] — Patol Fiziol Eksp Ter, 2010External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 3
This Testagen profile is compiled from published literature (4 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Testagen research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →